OBJECTIVE: This study is designed to (1) determine the perceived quality of care received by @entity1 with @entity135 at the end of their lives, in order to (2) better anticipate and improve upon the experiences of future @entity1 . STUDY DESIGN: Cross-sectional survey. SETTING: Single-institution, academic tertiary care medical center. SUBJECTS AND METHODS: A validated survey instrument, the Family Assessment of Treatment at the End of life (FATE), was administered to families of @entity1 who died of @entity135 (n = 58). The primary outcome was the overall FATE score. Independent variables included clinical characteristics, treatments received, and the care provided at the time of @entity204 . RESULTS: Overall FATE scores and the domains assessing management of symptoms and care at the time of @entity204 did not vary by disease status (logoregional vs distant @entity3 ) at the end of life (P = .989). The location of @entity204 in the home or in hospice (vs hospital) significantly improves scores in all 3 categories (P = .023). Involvement of a palliative care team improved the care at the time of @entity204 (P < .001), and palliative treatments (radiation and/or chemotherapy) improved scores in managing symptoms and care at the time of @entity204 (P = .011, P = .017). CONCLUSION: The FATE survey is a useful measure of the end-of-life experience of @entity135 @entity1 . Palliative treatments of @entity135 , @entity204 outside of the hospital, and palliative care team involvement all improve the end-of-life experience in this population.

End-of-life care among XXXX @entity1 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity135 :: (MESH:D006258,Disease) :: ['head and neck cancer']
